XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $6.89 and traded as high as $7.60. XBiotech shares last traded at $7.51, with a volume of 25,832 shares traded.
XBiotech Price Performance
The firm has a market capitalization of $217.47 million, a PE ratio of -7.00 and a beta of 1.41. The company has a fifty day moving average of $6.91 and a 200-day moving average of $7.10.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter.
Hedge Funds Weigh In On XBiotech
Several hedge funds and other institutional investors have recently added to or reduced their stakes in XBIT. American Century Companies Inc. acquired a new position in shares of XBiotech during the 2nd quarter worth $393,000. Rhumbline Advisers raised its holdings in XBiotech by 2,568.5% during the second quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company's stock valued at $103,000 after buying an additional 19,341 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of XBiotech by 102.9% in the second quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company's stock worth $505,000 after buying an additional 49,863 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of XBiotech by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company's stock worth $7,279,000 after acquiring an additional 13,804 shares in the last quarter. Finally, Empowered Funds LLC increased its holdings in shares of XBiotech by 7.9% during the 1st quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company's stock valued at $523,000 after acquiring an additional 4,725 shares during the last quarter. Institutional investors own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
See Also
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
